Windtree Therapeutics Yönetim

Yönetim kriter kontrolleri 2/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Jed Latkin

İcra Kurulu Başkanı

US$69.0k

Toplam tazminat

CEO maaş yüzdesi	67.29%
CEO görev süresi	less than a year
CEO sahipliği	n/a
Yönetim ortalama görev süresi	5.3yrs
Yönetim Kurulu ortalama görev süresi	1.2yrs

Son yönetim güncellemeleri

Recent updates

Windtree Therapeutics CEO Craig Fraser - Breaking Down Acute Heart Failure (Video)

Dec 06

Windtree Therapeutics: Addressing Underserved And Expensive Acute Conditions

Jul 06

Shareholders Will Likely Find Windtree Therapeutics, Inc.'s (NASDAQ:WINT) CEO Compensation Acceptable

Jun 09

Should You Take Comfort From Insider Transactions At Windtree Therapeutics, Inc. (NASDAQ:WINT)?

Feb 09

CEO Tazminat Analizi

Jed Latkin'un ücretlendirmesi Windtree Therapeutics'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2025	n/a	n/a	-US$24m
Mar 31 2025	n/a	n/a	-US$21m
Dec 31 2024	US$69k	US$46k	-US$5m

Tazminat ve Piyasa: Jed 'nin toplam tazminatı ($USD 69.02K ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın altındadır ($USD 607.94K ).

Tazminat ve Kazançlar: Jed şirketinin tazminatını şirket performansıyla karşılaştırmak için yeterli veri yok.

CEO

Jed Latkin (51 yo)

less than a year

Görev süresi

US$69,021

Tazminat

Mr. Jed A. Latkin has been the Chief Executive Officer of Windtree Therapeutics, Inc. since December 01, 2024 and is its President since December 01, 2024 and was its Independent Director since August 13,...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Jed Latkin	CEO, President & Director	less than a year	US$69.02k	Veri yok
Eric Curtis	Senior VP	5.6yrs	US$411.54k	0% $ 0
George Cox	Vice President of Technical Operations	no data	Veri yok	Veri yok
Pratap Paruchuru	Executive Director of Clinical Development	5.3yrs	Veri yok	Veri yok
Tracy Rarick	Head of Operations & Program Management	5.3yrs	Veri yok	Veri yok

5.3yrs

Ortalama Görev Süresi

57yo

Ortalama Yaş

Deneyimli Yönetim: WINT 'un yönetim ekibi deneyimli ve deneyimlidir ( 5.3 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Jed Latkin	CEO, President & Director	1.2yrs	US$69.02k	Veri yok
Mark Strobeck	Chairman of the Board	2.3yrs	US$56.22k	0.000010% $ 0.3
Saundra Pelletier	Independent Director	1.2yrs	US$23.37k	Veri yok
Andrew Kucharchuk	Independent Director	less than a year	Veri yok	Veri yok

1.2yrs

Ortalama Görev Süresi

52.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: WINT 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilmiyor ( 1.2 yıllık ortalama görev süresi), bu da yeni bir yönetim kurulu olduğunu gösteriyor.

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2025/10/05 06:23
Gün Sonu Hisse Fiyatı	2025/10/03 00:00
Kazançlar	2025/06/30
Yıllık Kazançlar	2024/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Windtree Therapeutics, Inc. 8 Bu analistlerden 1, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
John Tanner	Lazard Capital Markets
Leland Gershell	Oppenheimer & Co. Inc.
David Amsellem	Piper Sandler Companies

Windtree Therapeutics Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

High number of new and inexperienced directors

Windtree Therapeutics, Inc. Announces CFO Changes

Windtree Therapeutics, Inc. Announces Resignation of Craig Fraser from Board, Effective April 17, 2025

High number of new and inexperienced directors

Windtree Therapeutics, Inc. Appoints Leanne Kelly to Its Board of Directors and Chair of the Audit Committee

Windtree Therapeutics, Inc. Announces Chief Executive Officer Changes, Effective December 1, 2024

Recent updates

Windtree Therapeutics, Inc.(OTCPK:WINT) dropped from NASDAQ Composite Index

Nasdaq Determines to Delist Windtree Therapeutics, Inc.'s Common Stock from the Nasdaq Capital Market

Windtree Therapeutics, Inc. announced delayed 10-Q filing

Windtree Therapeutics, Inc. Terminates Its 04-CL-2201 Clinical Study, A Multcenter, Randomized, Placebo- Controlled, Parallel Group Trial on the Safety and Efficacy of Istaxime for Cardiogenic SCAI Stage C

Windtree Therapeutics, Inc. Announces Istaroxime Phase 2 Interim Analysis in SCAI Stage C Cardiogenic Shock Patients

Windtree Therapeutics, Inc. announced that it expects to receive $500 million in funding from Seven Knots, LLC

Windtree Therapeutics, Inc. announced that it expects to receive funding from Build & Build Corp. and other investors

Windtree Therapeutics, Inc. announced that it has received $0.07 million in funding

Price target decreased by 100% to US$4.00

High number of new and inexperienced directors

Windtree Announces Istaroxime Phase 2 Cardiogenic Shock Study Hits Enrollment Target for Planned Interim Analysis

Windtree Therapeutics, Inc. Announces CFO Changes

Windtree Therapeutics Receives a Deficiency Letter from the Nasdaq Listing Qualifications Department

Windtree Announces Publication of Istaroxime Positive Phase 2 SEISMiC B Study

Windtree Therapeutics, Inc. Receives Offer for Its Preclinical Oncology Drug Candidate

Windtree Therapeutics, Inc. (NasdaqCM:WINT) entered into a binding agreement to acquire Titan Environmental Solutions Inc. (OTCPK:TESI).

Windtree Therapeutics, Inc. Announces Istaroxime Cardiogenic Shock Scai Stage C Phase 2 Study Planned Interim Analysis Results for July 2025

Windtree Therapeutics, Inc. Announces Presentation of Preclinical Data on Istaroxime and A Selective Serc2a Activator At the European Society of Cardiology Heart Failure Conference

Windtree Therapeutics, Inc. Announces Istaroxime Exclusivity and Intellectual Property Potential Strategy for US

Windtree Therapeutics, Inc. announced that it expects to receive $2.5 million in funding

Windtree Therapeutics, Inc. Announces Resignation of Craig Fraser from Board, Effective April 17, 2025

Windtree Therapeutics, Inc. announced delayed annual 10-K filing

Windtree Therapeutics Regains Compliance with Nasdaq Listing Rules

New major risk - Share price stability

Windtree Therapeutics, Inc. Files Istaroxime Cardiogenic Shock and Prevention of Arrythmias Patent for India

Windtree Therapeutics Announces Reverse Stock Split to Allow the Company to Demonstrate Compliance with the Minimum Bid Price Requirement for Continued Listing on Nasdaq

High number of new and inexperienced directors

Windtree Announces Special Late-Breaking Clinical Science Abstract Presentation on Istaroxime At the Technology and Heart Failure Therapeutics Conference

Windtree Therapeutics, Inc. Appoints Leanne Kelly to Its Board of Directors and Chair of the Audit Committee

Windtree Therapeutics, Inc. Announces New Istaroxime Patent Filing for Preventing or Reducing the Risk of Acute Myocardial Arrhythmia

Windtree Therapeutics Receives Multiple Nasdaq Deficiency Notices

Windtree Therapeutics, Inc. announced delayed 10-Q filing

Windtree Therapeutics, Inc. Announces Chief Executive Officer Changes, Effective December 1, 2024

Windtree Therapeutics, Inc. Announces Expansion of Patents with Issuance of Istaroxime Patent for Hong Kong

Windtree Therapeutics, Inc. Initiates Enrollment in the SEISMiC C Trial in SCAI Stage C Cardiogenic Shock

Windtree Therapeutics, Inc. Announces Positive Phase 2b Topline Clinical Results with Istaroxime Significantly Improving Cardiac Function and Blood Pressure in Heart Failure Patients in Early Cardiogenic Shock

Windtree Announces Positive Topline Results from Its Phase 2B Seismic Extension Study of Istaroxime in Early Cardiogenic Shock

Windtree Therapeutics, Inc. Completes Enrollment of Phase 2b Study of Istaroxime in Early Cardiogenic Shock

Windtree Therapeutics, Inc., Annual General Meeting, Sep 24, 2024

Windtree Therapeutics, Inc. announced delayed 10-Q filing

Windtree Therapeutics, Inc. announced that it has received $1 million in funding

New major risk - Share price stability

Windtree Therapeutics, Inc. has withdrawn its Follow-on Equity Offering.

Windtree Therapeutics Provides Update on Istaroxime Clinical Development and Upcoming Clinical Trial Data

Windtree Therapeutics, Inc. announced that it has received $3.4 million in funding

New major risk - Revenue and earnings growth

Price target decreased by 89% to US$18.00

Windtree Therapeutics, Inc. has filed a Follow-on Equity Offering.

Windtree Therapeutics Regains Compliance with Nasdaq

Windtree Therapeutics Approves 1-for-18 Reverse Stock Split and Expects Compliance with Listing Requirements of the $1.00 Minimum Bid Price Requirement by The Nasdaq Capital Market

Windtree Therapeutics, Inc. (NasdaqCM:WINT) acquired All of the assets of Varian Biopharmaceuticals, Inc.

Windtree Therapeutics, Inc. announced delayed annual 10-K filing

Windtree Therapeutics Receives Non-Compliance Notice from Nasdaq

New major risk - Revenue and earnings growth

Windtree Therapeutics, Inc. Announces the Start of Patient Dosing in Phase 2 SEISMiC Extension Study of Istaroxime in Early Cardiogenic Shock

Windtree Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $2.054024 million.

New major risk - Share price stability

Windtree Therapeutics, Inc. Appoints Jamie McAndrew as Controller, Chief Accounting Officer and Principal Accounting Officer

Windtree Therapeutics, Inc. Is Developing A Multi-Asset Franchise of Its Novel Serca2a Activators

Windtree Therapeutics, Inc. Appoints Mark Strobeck to its Board of Directors

Windtree Therapeutics, Inc. Announces Chief Financial Official Officer Changes

Nasdaq Grants Windtree Therapeutics 180-Day Extension to Regain Compliance

Price target decreased to US$3.00

Windtree Therapeutics, Inc. Announces Impairment Charges for the Three Months Ended September 30, 2022

Windtree Therapeutics, Inc. Announces Positive Istaroxime Phase 2 Study in Early Cardiogenic Shock (Seismic) Published in the European Journal of Heart Failure

Windtree Therapeutics, Inc. Announces Istaroxime Late Breaker Abstract from its Positive Phase 2 Study in Early Cardiogenic Shock (SEISMiC) to be Presented at Heart Failure Society of America

Windtree Therapeutics, Inc. Reports Impairment for the Second Quarter Ended June 30, 2022

Windtree Is Leveraging Positive Istaroxime Early Cardiogenic Shock Results to Proactively Engage in Licensing Discussions and Explore Strategic Opportunities to Realize Greater Shareholder Value

Windtree Therapeutics Receives Non-Compliance Letter from Nasdaq